What is the recommended treatment for Meniere's disease?

Treatment of Ménière's Disease

Begin with patient education on dietary modifications (sodium restriction to 1500-2300 mg/day, limiting caffeine and alcohol) and trigger identification, then offer a limited course of vestibular suppressants for acute vertigo attacks, escalating to intratympanic steroids if conservative measures fail, followed by intratympanic gentamicin for refractory cases, and finally surgical options for those unresponsive to all medical therapy. 1

Stepwise Treatment Algorithm

Initial Conservative Management

Dietary and Lifestyle Modifications should be the first-line approach for all patients with Ménière's disease:

• Sodium restriction to 1500-2300 mg daily (based on American Heart Association recommendations, not specific Ménière's disease data) 1
• Limit caffeine consumption, as higher caffeine intake has been associated with increased symptoms in Ménière's disease patients compared to controls 1
• Restrict alcohol consumption 1
• Identify and avoid individual triggers including stress, allergies, barometric pressure changes, and specific foods through symptom journaling 1

The evidence for dietary modifications is limited (only one small negative RCT on sodium restriction), but compliance with these restrictions, particularly when supported by registered dietitian counseling, shows statistically significant relationships with vertigo improvement 1. Patients with lowest urinary sodium excretion after following low-sodium diet demonstrated better vertigo control and hearing improvements 1.

Acute Vertigo Attack Management

Vestibular suppressants should be offered for a limited course during acute attacks only 1:

• Antivertigo medications for symptomatic relief during attacks 1
• Antiemetics for nausea management 1
• Benzodiazepines carry significant risk for drug dependence and should be used cautiously 1
• Anticholinergics (scopolamine, atropine) can suppress acute attacks but have significant side effects including blurred vision, dry mouth, urinary retention, and sedation 1

Critical caveat: Vestibular suppressants should NOT be used continuously for prevention, only during acute episodes 1.

Medical Pharmacotherapy

Oral medications may be considered, though evidence is very uncertain 2:

• Diuretics to remove excess body fluid 1
• Betahistine (histamine analogue to increase inner ear vasodilation) 1
• Antihistamines for patients with concurrent allergies (up to 30% of Ménière's disease patients have allergies contributing to symptoms) 1

A 2023 Cochrane review found very low-certainty evidence for all systemic pharmacological interventions (betahistine, diuretics, antivirals, corticosteroids), meaning we cannot confidently determine their true effects 2.

Intratympanic Therapy for Active Disease

For patients failing conservative measures and oral medications:

Intratympanic steroids may be offered as first-line invasive therapy 1:

• Hearing-preserving option for active Ménière's disease 1
• Network meta-analysis shows methylprednisolone is equally effective as gentamicin for long-term vertigo control (≥24 months follow-up) without the hearing loss risk 3
• No standardized protocol exists for dosing or titration 1

Intratympanic gentamicin should be offered for patients not responsive to nonablative therapy 1:

• Most efficacious medication for vertigo control according to network meta-analysis 3
• Major caveat: Carries risk of hearing loss, making it a partially ablative procedure 3
• No standardized protocol for optimal dosage or titration 1
• Should be reserved for patients who have failed less aggressive interventions 1

Surgical Options for Refractory Disease

For patients failing medical management and intratympanic therapies:

Hearing-sparing procedures:

• Endolymphatic sac decompression has been widely adopted internationally due to high vertigo control rates with low risk of audiovestibular loss 4
• Vestibular nerve section (hearing-sparing ablative procedure) 1
• Triple semicircular canal occlusion (TSCO) is an emerging partially ablative technique showing promise with high vertigo control rates 4

Hearing-ablative procedures for severe refractory cases with nonusable hearing:

• Labyrinthectomy (complete vestibular ablation) 1
• May be combined with cochlear implantation for hearing rehabilitation 4

Adjunctive Therapies

Vestibular rehabilitation/physical therapy should be offered to patients who have failed less definitive therapy, particularly those with nonusable hearing or after ablative procedures 1:

• Addresses long-term balance issues and imbalance 1
• May help with anxiety associated with Ménière's disease 1
• Critical for compensation after labyrinthectomy, especially important given eventual bilateral disease development risk 1

Hearing aids for hearing loss management 1

Migraine prophylaxis should be considered in recalcitrant cases, as concurrent migraine symptoms may contribute to disease burden 1, 5

What NOT to Do

Do not prescribe positive pressure therapy - this has been specifically recommended against by the American Academy of Otolaryngology-Head and Neck Surgery 1

Do not use vestibular suppressants continuously - only for acute attacks 1

Disease Staging Considerations

Treatment intensity should match disease severity 1:

• Mild disease (occasional mild vertigo, minimal hearing loss): Conservative management with dietary modifications
• Moderate disease (occasional moderate-severe attacks): Add oral medications and consider intratympanic steroids
• Severe disease (frequent debilitating episodes): Progress to intratympanic gentamicin or surgical options

Critical Monitoring

Document at each visit 1:

• Resolution, improvement, or worsening of vertigo
• Changes in tinnitus and hearing loss
• Quality of life impact
• Obtain audiogram for ongoing hearing assessment 1